Fulgent Genetics, Inc. (FLGT) is a leading technology company specializing in developing and commercializing comprehensive genetic testing solutions to deliver precision medicine for the global health community. The company is based in Temple City, California, and has been operating since 2011 with the mission to make high-quality genetic testing accessible to patients and healthcare providers.
Fulgent Genetics, Inc. utilizes its proprietary technology platform to perform large-scale, next-generation gene sequencing (NGS), which allows for the detection of a broad spectrum of diseases and conditions. Its unique approach combines advanced bioinformatics and industry-leading data science to provide comprehensive genetic reports, making it a game-changer in the genetics and genomics field.
The company offers a wide range of tests across various medical specialties and situations, including oncology, reproductive health, medical genetics, and neurology. Fulgent Genetics' tests are designed to provide physicians and caregivers with critical information to assist in the diagnosis, management, and treatment of diseases and conditions.
Fulgent Genetics, Inc. prides itself on its clinical-quality genetic test offerings, which are flexible, scalable, and customizable, allowing the company to adapt to the ever-evolving field of genetics. Its capabilities range from single gene tests to whole genome sequencing, thereby supporting a wide spectrum of genetic analysis needs.
Another significant contribution of Fulgent Genetics' approach is its commitment to research and development. The company continually invests in developing new technologies and improving existing ones, ensuring it remains at the forefront of the genetic testing industry.
Moreover, Fulgent Genetics, Inc. is a publicly-traded company listed on NASDAQ under the ticker symbol "FLGT." Despite a volatile market, the company has shown strong resilience and consistent growth, thanks in part to its adaptable business model, commitment to innovation, and unwavering focus on providing high-quality genetic testing solutions.
In conclusion, Fulgent Genetics, Inc. represents a leading-edge standard in the global genetic testing industry. Their comprehensive range of genetic testing services, combined with an adaptable business model, positions them as a significant player in the evolving landscape of precision medicine. By leveraging advanced technologies and a multidisciplinary approach, the company continues to make positive advancements in healthcare science, benefiting patient lives worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article compares two cancer diagnostics companies, Precipio, Inc. (PRPO) and Fulgent Genetics, Inc. (FLGT), to determine which offers more upside potential for investors. While PRPO focuses on hematologic cancers and is expanding its product sales, FLGT provides a broader range of genetic testing services, integrated acquisitions, AI capabilities, and a therapeutic development business. The analysis concludes that FLGT appears to have more upside due to its diversified platform, strategic acquisitions, and more reasonable valuation compared to PRPO.
UBS Asset Management significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 55.6% in the second quarter, selling 56,283 shares and retaining 45,020 shares valued at approximately $924,000. Institutional investors now own 48.06% of the company. Additionally, Fulgent Genetics insiders, including Hanlin Gao and Jian Xie, sold 5,932 shares worth $117,156, primarily to cover tax obligations from vested equity awards. The company also reported missing consensus estimates for quarterly EPS and revenue, and analysts currently maintain a "Hold" rating with an average price target of $27.50.
The Public Employees Retirement System of Ohio has acquired a new stake of 55,247 shares in Fulgent Genetics, Inc. valued at approximately $1.13 million. This investment comes as institutional ownership in the company reaches 48.06%, despite Fulgent Genetics reporting weaker-than-expected quarterly results and maintaining negative profitability. Analyst sentiment is mixed, with a "Hold" rating, and two insiders recently sold shares to cover tax obligations.
Fulgent Genetics' COO, Jian Xie, sold 2,127 shares of the company's stock for approximately $41,816.82, primarily to cover tax obligations on vested equity awards. This sale decreased his holdings to 359,924 shares. The company's stock experienced a 1.9% dip, and its latest quarterly results missed analyst expectations with an adjusted EPS loss of $0.58 and revenue of $85.39 million.
Hanlin Gao, an insider at Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares worth $32,891.18 to cover tax withholdings on vested equity awards, reducing his stake by 0.17%. This sale follows another recent transaction of 939 shares. The company recently reported a quarterly loss of $0.58 per share, missing consensus estimates, and revenue of $85.39 million, also below expectations, leading to a consensus "Hold" rating from analysts with an average price target of $27.50.
Wall Street Zen upgraded Fulgent Genetics (NASDAQ:FLGT) from a "strong sell" to a "sell" rating, although the overall analyst consensus remains "Hold" with a target price of $27.50. The company recently reported an adjusted loss of $0.58 per share and missed revenue estimates for the latest quarter. Despite this, institutional investors own 48.06% of the company, and insiders recently sold shares primarily to cover tax obligations.
Jian Xie, COO of Fulgent Genetics (NASDAQ:FLGT), sold 1,193 shares of the company's stock for $23,752.63 to cover tax obligations. This sale reduced his holdings to 362,051 shares. The company recently reported weaker-than-expected quarterly results and currently holds a "Hold" rating from analysts with a consensus price target of $27.50.